Striking the Balance: Community Experts Come Together for High-Level Dialogue on Cancer Care Read more about Striking the Balance: Community Experts Come Together for High-Level Dialogue on Cancer Care
New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer Read more about New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer
Amgen to Present at the Jeffries Global Life Sciences Conference Read more about Amgen to Present at the Jeffries Global Life Sciences Conference
New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer Read more about New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture Read more about FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union Read more about Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting Read more about Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients Read more about Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients
Amgen Announces Voting Results of Annual Meeting of Stockholders Read more about Amgen Announces Voting Results of Annual Meeting of Stockholders
Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California Read more about Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California
